GA-CYBLE
11.5.2021 10:44:12 CEST | Business Wire | Press release
Cyble, an AI-powered, Y Combinator-backed, cyber intelligence company that empowers organizations with darkweb/cybercrime monitoring and mitigation services, today announced the addition of eminent technology and sustainability evangelist Vijay Sethi to its Advisory Board. Vijay has rich experience in advising and mentoring corporates and startups in various facets of management, digital transformation, and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005525/en/
“A key member of our Advisory Board, Vijay’s insights will help steer our strategic development initiatives. His appointment is in line with Cyble’s commitment to achieving our goals by ensuring sustained growth, maintaining operational excellence, establishing a culture of innovation, and raising the standards for corporate governance. As Cyble continues to deliver advanced threat intelligence to its end-clients, I look forward to working with Vijay as Cyble continues to grow and span across uncharted territories,” says Manish Chachada, COO and Co-founder of Cyble.
An industry veteran with over 30 years of experience, Vijay Sethi has served as the CIO, CHRO, and Head CSR at Hero MotoCorp. Prior to that, he worked with Ranbaxy and Tata Consultancy Services. A huge proponent of digital technologies like the Cloud, Mobility, Artificial Intelligence, RPA, AR, VR, and cybersecurity and risk management, he has experience in digital transformation roadmap and project development ventures, large-scale IT projects, community development programs, and talent development and employee engagement campaigns.
Commenting on joining forces with Cyble, Vijay says, “I strongly endorse the growing need to make the digital world safer and help share cybersecurity insights and threat intelligence with consumers. The team at Cyble, their technological offerings, and the company’s commitment to keeping customers and users safe are impressive. I’m very pleased to be joining Cyble as an Advisor and look forward to working with its talented and dynamic teams.”
Rated among India’s Best IT leaders, over the years, Vijay has won several prestigious recognitions, including CIO of the year many times, CIO Hall of Fame, Super League CIO, Champion CIO, Global CIO, Global CIO Hall of fame, Digital Icon of India, India’s Best IT manager, India’s Most Innovative CSR Leader, and many others. He also serves as the Chairman of SAP India User Group (INDUS). Earlier, he also served as the Chairman of the IT Committee of Society of the Indian Automobile Manufacturers (SIAM) and the Chairman of CSR Committee of SIAM. Over the years, Vijay has also been a member of various Committees of CII and FICCI.
Beenu Arora, CEO and Founder of Cyble, says, “I am delighted to welcome Vijay into the board. He truly needs no introduction in the cybersecurity fraternity, and his problem-solving skills and passion for building efficient solutions make him best suited to take Cyble to the next level. His appointment has been a significant step in our effort to nurture our world-class business leadership team. Vijay’s actionable counsel will prove beneficial in shaping Cyble’s strategic business decisions.”
About Cyble:
Cyble is a global threat intelligence SaaS provider that helps enterprises protect themselves from cybercrimes and exposure in the Darkweb. Its prime focus is to provide organizations with real-time visibility to their digital risk footprint. Backed by Y Combinator as part of the 2021 winter cohort, Cyble has also been recognized by Forbes as one of the top 20 Best Cybersecurity Start-ups To Watch In 2020. Headquartered in Alpharetta, Georgia, and with offices in Australia, Singapore, and India, Cyble has a global presence. To learn more about Cyble, visit www.cyble.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005525/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes12.5.2026 08:00:00 CEST | Press release
Merz Therapeutics to present 11 abstracts at ISPRM World Congress 2026, highlighting its commitment to improving outcomes for people living with movement disorders Updated analysis indicates that optimizing botulinum toxin dosing over multiple injection cycles may be an important factor in improving outcomes in people living with limb spasticity, with available clinical data suggesting support for flexible, individualized dosing with incobotulinumtoxinA (XEOMIN®) Updated meta-analyses examining secondary treatment failure and neutralizing antibodies suggest a potential for sustained long-term treatment response with incobotulinumtoxinA (XEOMIN®) Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced it will present 11 scientific abstracts at the International Society of Physical and Rehabilitation Medicine (ISPRM) 2026 World Congress. Taking place from May 17th to May 21st in Vancouver, Canada, the presentations will feature key data on optimal dosin
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook12.5.2026 07:30:00 CEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 +3.1% Adjusted EBITDA (4) 404 280 +57.0% 425 +5.0% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralise currency variations 3) ‘Like-for-like basis’ is as if Intelsat fully consolidated from 1 January 2024 4) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +106.0% yoy(1) supported by growth in Mobility (+207.8% yoy(1); including positive impact from a contract restructuring in Aviation) and Gov
GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI12.5.2026 03:00:00 CEST | Press release
GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/ GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure. Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment. Deployable: modular clusters engineered for rapid implementation across diverse environments.
INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 21:49:00 CEST | Press release
INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom